Annexon CFO Jennifer Lew sells shares worth over 6,500 - Investing.com
| ANNX Stock | USD 5.14 0.03 0.58% |
Slightly above 61% of Annexon's investor base is looking to short. The analysis of the overall investor sentiment regarding Annexon suggests that many traders are alarmed. Annexon's investing sentiment can be driven by a variety of factors including economic data, Annexon's earnings reports, geopolitical events, and overall market trends.
Annexon |
Annexon CFO Jennifer Lew sells shares worth over 6,500 Investing.com
Read at news.google.com
 |
Annexon Fundamental Analysis
We analyze Annexon's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annexon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annexon based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Annexon is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Annexon Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Annexon stock to make a market-neutral strategy. Peer analysis of Annexon could also be used in its relative valuation, which is a method of valuing Annexon by comparing valuation metrics with similar companies.
Peers
Annexon Related Equities
| GPCR | Structure Therapeutics | 11.00 | ||||
| IMMX | Immix Biopharma | 6.55 | ||||
| INZY | Inozyme Pharma | 4.46 | ||||
| RCUS | Arcus Biosciences | 2.94 | ||||
| DAWN | Day One | 2.85 | ||||
| CGEM | Cullinan Oncology | 2.62 | ||||
| ABOS | Acumen Pharmaceuticals | 2.60 | ||||
| RLAY | Relay Therapeutics | 2.37 | ||||
| AMLX | Amylyx Pharmaceuticals | 1.54 | ||||
| WVE | Wave Life | 0.56 | ||||
| BPMC | Blueprint Medicines | 2.56 | ||||
| INAB | In8bio | 3.03 | ||||
| HEPA | Hepion Pharmaceuticals | 4.35 | ||||
| ZURA | Zura Bio | 6.83 | ||||
| CNSP | Cns Pharmaceuticals | 7.69 | ||||
| XFOR | X4 Pharmaceuticals | 8.11 |
Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.